Intellikine Raises $51 Million
Intellikine Inc., a La Jolla, Calif.-based developer of small molecule drugs for cancer, inflammation and autoimmune diseases, has raised $51 million in Series B funding. Novartis Bioventures led the round, and was joined by U.S. Venture Partners, Biogen Idec and FinTech Global Capital. Return backers included Abingworth, CMEA Capital and Sofinnova Ventures. The round includes a $28.5 million initial calldown, with the remainder dependent on the achievement of certain milestones. Intellikine previously raised $12.5 million.
9 July 2009•3 mins read
